FDA 483 - Morton Grove Pharmaceuticals, Inc.

Morton Grove Pharmaceuticals received a Form 483 detailing significant deficiencies across its quality control unit, laboratory operations, and manufacturing processes. The inspection revealed issues including data integrity concerns, inadequate investigations into discrepancies, and failures in equipment maintenance and environmental controls. These findings indicate a lack of adherence to cGMP requirements, potentially impacting the quality and purity of distributed drug products.